Valuation: Gilead Sciences, Inc.

Market Cap 162B 142B 132B 122B 228B 15,672B 232B 1,581B 617B 7,644B 608B 594B 26,519B P/E 2026 *
-47x
P/E 2027 * 16.5x
Enterprise Value 171B 151B 140B 129B 241B 16,588B 246B 1,674B 653B 8,091B 643B 629B 28,069B EV / Sales 2026 *
5.63x
EV / Sales 2027 * 5.01x
Free-Float
99.88%
Yield 2026 *
2.53%
Yield 2027 * 2.62%
1 day-1.27%
1 week-3.95%
Current month+3.62%
1 month+4.69%
3 months-2.04%
6 months-3.69%
Current year+6.66%
1 week 127.61
Extreme 127.61
140.61
1 month 123.67
Extreme 123.67
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%-3.95%+15.28%+68.57% 162B
+1.92%+1.35%+48.33%+157.98% 1,037B
+1.42%+3.73%+53.34%+51.57% 615B
+1.38%+0.92%+34.73%+79.30% 448B
+5.14%+5.84%+37.54%+27.28% 326B
+1.85%+4.64%+38.53%+39.87% 293B
-0.11%+0.97%+22.57%+17.81% 264B
+0.25%-3.10%-24.44%-42.25% 216B
+1.49%+0.05%+20.22%+57.91% 198B
+0.73%-0.50%-1.36%-33.31% 141B
Average +1.22%+1.01%+24.47%+42.47% 369.89B
Weighted average by Cap. +1.39%+1.42%+34.86%+71.65%

Financials

2026 *2027 *
Net sales 30.42B 26.76B 24.86B 22.86B 42.87B 2,946B 43.64B 297B 116B 1,437B 114B 112B 4,985B 32.28B 28.39B 26.38B 24.26B 45.49B 3,126B 46.31B 315B 123B 1,525B 121B 119B 5,290B
Net income -3.39B -2.98B -2.77B -2.55B -4.78B -328B -4.86B -33.13B -12.92B -160B -12.73B -12.46B -556B 9.76B 8.59B 7.98B 7.34B 13.76B 945B 14B 95.38B 37.2B 461B 36.65B 35.86B 1,600B
Net Debt 9.46B 8.32B 7.73B 7.11B 13.33B 916B 13.57B 92.43B 36.05B 447B 35.52B 34.75B 1,550B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-23 $130.86 +0.40% 6,298,021
26-07-22 $130.34 +0.05% 4,757,764
26-07-21 $130.28 -2.20% 8,371,109
26-07-20 $133.21 -0.80% 4,103,979
26-07-17 $134.28 -1.48% 6,903,235
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
130.34USD
Average target price
157.56USD
Spread / Average Target
+20.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock